News headlines about Edwards Lifesciences (NYSE:EW) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Edwards Lifesciences earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.7442208897752 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Commit To Purchase Edwards Lifesciences Corp At $123, Earn 45.1% Annualized Using Options – Nasdaq (nasdaq.com)
- Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings (finance.yahoo.com)
- Edwards Lifesciences’ (EW) THVT Likely to Drive Q4 Earnings (zacks.com)
- [$$] Biomedical Startup Investor Epidarex Capital Plans Expansion (finance.yahoo.com)
- Comparing Edwards Lifesciences (EW) & IRIDEX (IRIX) (americanbankingnews.com)
Several brokerages have recently weighed in on EW. Barclays reiterated an “equal weight” rating and set a $120.00 price objective on shares of Edwards Lifesciences in a report on Saturday, September 30th. Canaccord Genuity reiterated a “buy” rating and set a $135.00 price objective (down previously from $155.00) on shares of Edwards Lifesciences in a report on Wednesday, October 25th. Evercore ISI began coverage on shares of Edwards Lifesciences in a report on Wednesday, January 3rd. They set an “outperform” rating and a $140.00 price objective on the stock. Zacks Investment Research lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 26th. Finally, Deutsche Bank dropped their price objective on shares of Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating on the stock in a report on Thursday, October 26th. Six equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $129.57.
Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The company’s revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.68 earnings per share. equities research analysts predict that Edwards Lifesciences will post 3.76 earnings per share for the current year.
Edwards Lifesciences announced that its board has approved a stock repurchase program on Thursday, December 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.
In other news, VP Larry L. Wood sold 6,300 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $121.00, for a total transaction of $762,300.00. Following the completion of the sale, the vice president now directly owns 116,148 shares of the company’s stock, valued at $14,053,908. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $101.12, for a total transaction of $535,936.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 197,820 shares of company stock valued at $21,760,908. 2.13% of the stock is currently owned by insiders.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.